Skinvisible Inc. and Cambrex Corp. have signed a joint agreement for the R&D of acne formulations based on a new delivery of benzoyl peroxide. The formulations will be created utilizing Invisicare, Skinvisible’s patented polymer delivery system and Cambrex’s benzoyl peroxide (BPO).
Invisicare’s non-occlusive technology is a combination of hydrophilic and hydrophobic polymers that hold actives on the skin for extended periods of time resisting both wash-off and perspiration. It controls the release of actives, reducing irritation and eliminating some manufacturing processes.
According to Skinvisible, controlling the release of active ingredients such as BPO can result in the use of less active ingredient. Because high levels of BPO can cause irritation in acne products, this delivery system may benefit both the manufacturer and the consumer.